| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | lanthanum (Fosrenol®) |
| Formulation | 750 mg and 1000 mg oral powder |
| Reference number | 1758 |
| Indication | Phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Lanthanum is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels |
| Company | Shire Pharmaceuticals Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 21/08/2012 |